青光眼
医学
眼压
失明
临床试验
重症监护医学
眼科
疾病
随机对照试验
验光服务
外科
内科学
作者
Hari Jayaram,Miriam Kolko,David S. Friedman,Gus Gazzard
出处
期刊:The Lancet
[Elsevier]
日期:2023-09-21
卷期号:402 (10414): 1788-1801
被引量:73
标识
DOI:10.1016/s0140-6736(23)01289-8
摘要
The glaucomas are a group of conditions leading to irreversible sight loss and characterised by progressive loss of retinal ganglion cells. Although not always elevated, intraocular pressure is the only modifiable risk factor demonstrated by large clinical trials. It remains the leading cause of irreversible blindness, but timely treatment to lower intraocular pressure is effective at slowing the rate of vision loss from glaucoma. Methods for lowering intraocular pressure include laser treatments, topical medications, and surgery. Although modern surgical innovations aim to be less invasive, many have been introduced with little supporting evidence from randomised controlled trials. Many cases remain undiagnosed until the advanced stages of disease due to the limitations of screening and poor access to opportunistic case finding. Future research aims to generate evidence for intraocular pressure-independent neuroprotective treatments, personalised treatment through genetic risk profiling, and exploration of potential advanced cellular and gene therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI